abstract |
Triazole compounds of the general Formula (1) wherein: R 1 represents H, C 1-6 alkyl, optionally substituted by OH, C 1-6 alkyl, halogen or phenyl, C 3-6 cycloalkyl; R 2 represents H, C 1-6 alkyl, optionally substituted by OH, C 1-6 alkyl, halogen or phenyl, C 1-6 alkoxy, C 1-6 alkylthio, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, halogen, CN, COOR3, CONR3R4, NR3R4, SO2R3, SO2NR3R4, or an aromatic moiety, selected from phenyl, naphthyl and a 5 or 6 membered heterocyclic moiety with 1, 2, 3 or 4 heteroatoms, independently selected from each other from O, N and S, the aromatic moiety being able to present one or two substituents, independently selected from each other from C 1-6 alkyl, optionally substituted by OH, C 1-6 alkyl, halogen or phenyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C3-6 cycloalkyl, halogen, CN, COR3, NR3R4, NO2, SO2R3, SO2NR3R4 and phenyl, optionally substituted by one or two moieties independently selected from each other from C1-6 alkyl, C1-6 alkoxy, NR3R4, CN, CF3, CHF2 or halogen; R3 and R4 independently represent each other H, C1-6 alkyl optionally substituted by OH, OC1-6 alkyl, halogen or phenyl; A represents C4-10 alkylene or C3-10 alkylene, comprising at least one Z group, selected from O, S, CONR3, COO, CO, C3-6 cycloalkyl and a double or triple bond; Bs means a remainder of Formulas (a) or (b) where: X represents CH2 or CH2CH2; Y represents CH2 or O; R6 and R7 are independently selected from one of H, C1-6 alkyl optionally substituted by halogen; OH, C1-6 alkoxy, C2-6 alkenyl, CN, NO2, CO2R3, SO2R3, SO2NR3R4; as well as salts with physiologically compatible acids. Pharmaceutical composition containing, at least one compound of the general Formula (1), optionally together with vehicle and / or physiologically acceptable auxiliary substances. Use of at least one compound of the general Formula (1) for the preparation of said pharmaceutical composition for the treatment of diseases that respond to the action of agonists and / or antagonists of D3 dopamine receptors |